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Background: The ideal therapeutic option for ventilator associated pneumonia caused by
carbapenem-resistant Enterobacteriaceae is not deﬁned. The aim of this study was to assess
mortality-associated risk factors in patients with VAP by CRE and determine the outcome
of  several treatment options.
Methods: This was a retrospective study performed in two tertiary hospitals involving
patients with VAP caused by CRE between January 2010 and August 2014. The outcomes
were mortality within 30 days of VAP diagnosis and overall mortality during hospital admis-
sion. Risk factors for mortality were assessed by comparing variables of survivors and
non-survivors.
Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male,
median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality
was  67%. In the binary logistic regression analysis, only age >50 years was independently
associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by
tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was
used  by 17 patients (20.8%). No therapeutic option was independently associated to survival.
However, combined therapy with two active drugs was superior to the therapy with a sin-
gle  active drug when inappropriate therapy was the comparator (p = 0.044). The addition of
carbapenem was not associated with increased survival.
Conclusion: The best therapeutic option for VAP by CRE is still not completely deﬁned, buteast tthe  therapy with at lPlease cite this article in press as: Tuon FF, et al. Risk factors for mort
carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2016. http://dx
©  2016 Sociedade Brasil
open  access article unde
∗ Corresponding author.
E-mail address: ﬂptuon@gmail.com (F.F. Tuon).
ttp://dx.doi.org/10.1016/j.bjid.2016.09.008
413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by E
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)wo active drugs was superior in this study.ality in patients with ventilator-associated pneumonia caused by
.doi.org/10.1016/j.bjid.2016.09.008
eira de Infectologia. Published by Elsevier Editora Ltda. This is an
r the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
lsevier Editora Ltda. This is an open access article under the CC
.
ARTICLE IN PRESSBJID-654; No. of Pages 6
 . 2 0 12  b r a z j i n f e c t d i s
Introduction
Emergence of Klebsiella pneumoniae carbapenemase (KPC)
among Enterobacteriaceae has severely challenged antimicro-
bial therapy, as it provides high-level resistance to all beta-
lactams and distinct levels of resistance to carbapenems.1
The best therapy for carbapenem-resistant Enterobacteri-
aceae (CRE) is not well deﬁned in medical literature. Some
authors have suggested combined therapy based on few retro-
spective clinical studies, as well as in vitro and in vivo models.2,3
Polymyxins, aminoglycosides, and tigecycline have been
used as core treatment drugs, considering local susceptibil-
ity patterns.4,5 Other drugs may be suggested according to
infection site, such as fosfomycin for urinary tract infection.6
Ventilator-associated pneumonia (VAP) is still one of the main
infections in intensive care units. Microbiological etiology
of VAP widely varies according to local epidemiology. The
incidence of CRE has increased in Southern Brazil, mainly
associated with VAP.7,8 Studies on the treatment of CRE
causing VAP (CRE-VAP) are scarce, only case reports and
small series are available.9–11 Risk factors associated with
mortality and the optimal treatment of CRE-VAP are not well-
established. The main objective of this study was to describe
risk factors associated with CRE-VAP mortality. Secondary
objective was to determine the outcome with different antibi-
otic regimens.
Methods
Study  design
A cross-sectional study was carried out at two tertiary-care,
trauma and surgery reference hospitals, in South of Brazil,
with a total number of 870 beds and 58 intensive care unit
beds. All patients aged ≥16 years with VAP caused by CRE in
the period from January 2010 to August 2014 were included in
the study. Only the ﬁrst episode of each patient was analyzed.
Data were collected from medical charts and/or hospital com-
puter system databases. This study was approved by the Ethics
Committee of FEPAR (42918014.1.0000.0103).
Microbiological  procedures
All included patients had positive quantitative cultures
for CRE obtained from the respiratory tract through bron-
choalveolar lavage (BAL) (>104 CFU/mL) or tracheal aspira-
tion (>106 CFU/mL). The BAL methodology was previously
described by our study-group.12
All identiﬁed bacteria were tested for susceptibility by
disk diffusion method and/or Gram-negative card for auto-
mated method according to the CLSI guidelines.13 Minimal
inhibitory concentration (MIC) was determined by automated
method in mg/L (Vitek 2
®
, Biomérieux, Marcy-LÉtoile, France)
and/or E-test method, as recommended. Screening for CRE
13Please cite this article in press as: Tuon FF, et al. Risk factors for mor
carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2016. http://dx
was performed with modiﬁed Hodge’s test according to CLSI.
Modiﬁed Hodge’s test positive isolates were submitted to
PCR for blaKPC ampliﬁcation using Easy Q KPC (Biomérieux,
Marcy-LÉtoile, France) with Escherichia coli ATCC 25922 and 6;x x x(x x):xxx–xxx
blaKPC-carrying K. pneumoniae strain ATCC BAA-1705 as nega-
tive and positive controls, respectively.14 Brieﬂy, the ampliﬁed
product was puriﬁed using Exonuclease I and Shrimp Alkaline
Phosphatase (ExoSAP, USB Corporation) for DNA sequenc-
ing. Sequencing reactions were performed using BigDye v1.1
Sequencing Kits (Applied Biosystems, Foster City, CA, USA).
Sequence data were acquired on ABI 3100 (Applied Biosys-
tems Inc., CA). The gene sequences were compared to entries
in databases queried by NCBI BLAST (nucleotide sequence
database; available at http://www.ncbi.nlm.nih.gov/).
Variables  and  deﬁnitions
VAP was deﬁned according to CDC criteria.15 Other crite-
ria, such as diagnostic scores/indexes or clinical impression
were excluded. Patients with concomitant infections were
excluded. Secondary bacteremia was not evaluated. Potential
risk factors assessed were: age, gender, Charlson comorbid-
ity index (and all comorbidities were evaluated separately),16
APACHE II,17 burn, HIV infection, chronic corticoid use, trauma
on admission, elective or emergency surgery, length of hos-
pitalization and mechanical ventilation duration before VAP,
and previous antibiotic use during current hospitalization.
Risk was neither adjusted for sepsis nor pneumonia severity
scores.
Antimicrobial  therapy
Antimicrobial treatment was deemed inappropriate if antibi-
otics initially prescribed were not active against the identiﬁed
pathogens based on in vitro susceptibility testing. Appropri-
ate therapy was deﬁned by active drug use with adequate
schedule in two situations for additional analysis: antibiotic
started within the ﬁrst 24 h with no switches; and treatment
adjustment within ﬁve days (arbitrarily deﬁned considering
average time of culture results). For analysis of different antibi-
otics schedules, the term monotherapy was used when a
single drug was active against CRE and combined therapy
whenever two or more  drugs were active considering in vitro
susceptibility. The dose of antibiotics was also evaluated.
Polymyxin B was used without loading dose and renal adjust-
ment (30,000 IU/kg); meropenem dose ranged from 1 g to 2 g
each 8 h with renal adjustment; tigecycline is used with dou-
bled dose (100 mg  q12 h) without renal adjustment; amikacin
dose was 15 mg/kg without loading dose and renal adjust-
ment.
Statistical  analysis
All statistical analyses were carried out using SPSS 18.0.
Bivariate analysis was performed separately for each variable.
p-Values were calculated using the 2 test or Fisher’s exact
test for categorical variables and Student’s t-test or Wilcoxon
rank-sum test for continuous variables. Variables for which
the p-value was ≤0.10 in the univariate analysis were includedtality in patients with ventilator-associated pneumonia caused by
.doi.org/10.1016/j.bjid.2016.09.008
in a logistic regression model. A p-value of 0.05 was set as
the limit for acceptance or removal of the new terms in the
model. Goodness-of-ﬁt was assessed by Hosmer–Lemeshow
test. Thirty-day mortality curves were constructed and
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Fig. 1 – Mortality curve of 112 patients with
ventilator-associated pneumonia caused by
Carbapenem-resistant Enterobacteriaceae. The curve
compares mortality of patients receiving adequate therapy
as monotherapy or combined as well as inadequateb  r a z j i n f e c t d i s .
ehan-Breslow-Wilcoxon test was performed. All tests were
wo-tailed, and a p-value ≤0.05 was considered signiﬁcant.
esults
 total of 112 patients with CRE-VAP were included in
he study, with 102 cases of K. pneumoniae and 10 cases
f Enterobacter aerogenes. Male was the predominant gender
n = 73, 65.2%) and global mean age was 54.9 ± 20.7 years-old
median = 56). The mean hospital stay was 47.7 ± 57.6 days
median = 31 days), mean duration of hospitalization before
RE-VAP 18.6 ± 21.0 days (median = 14 days). The mean ICU
tay after CRE-VAP was 14.8 ± 8.3 days (median = 10 days). The
harlson index was low (mean = 1.55 ± 2.36). Data are detailed
n Table 1.
Thirty-day mortality was 57.1% (64/112) for all CRE-VAP
atients and in-hospital global mortality was 67.0% (75/112).
ging, high Charlson index, chronic renal failure, systemic
rterial hypertension, neoplasm, and trauma on admission
ere the clinical ﬁndings associated with increased mortal-
ty. These data were evaluated in a binary logistic regression
nd only age > 50 years old was independently associated with
ncreased mortality (Table 2).
Out of 112 patients, only 31 (27.7%) received at least one
ctive drug within 24 h of VAP diagnosis (ﬁrst clinical signs
lus altered chest x-ray). After ﬁve days from the diagno-
is, 83 patients (74.1%) received at least one active drug; 66
atients received one active drug and 17 (20.8%) received
wo active drugs for CRE-VAP. Polymyxin B (1,500,000 IU to
,000,000 IU/day) was the preferred active drug (47.5%), fol-
owed by tigecycline (29.2%) and amikacin (1000 mg/day)
2.4%). From 17 patients with two active drugs, polymyxin
 with tigecycline was the preferred combination (15/17).
espite of the high MIC  for meropenem in all clinical samples
rom the respiratory tract (MIC ≥16 mg/L), meropenem was
ombined with at least one active drug in 49 patients (59.8%).
ne patient was treated with two carbapenems (ertapenem
lus meropenem) with good clinical outcome. None of these
herapeutic options were independently associated with sur-
ival. However, combined therapy (two active drugs) had
igniﬁcantly lower mortality than monotherapy (only one
ctive drug) (p = 0.044). Combination of meropenem was not
ssociated with improved survival.
After culture results, 83 patients received adequate therapy
74%). From 29 patients (26%) who maintained inappropriate
reatment after culture results, one third (nine patients) had
rogressed to death upon disclosure of culture result. Despite
aving a low Charlson index, the assessed patients had high
PACHE II score, ranging from 9 to 33, mean and median of 26
nd 27, respectively.
Considering the fact that age was an independent mor-
ality risk factor and combination therapy was a protective
actor, age was dichotomized (≥50 years old and <50 years
ld), according to mortality and antibiotic adequacy. Antibi-
tic adequacy did not change mortality in patients with ≥50Please cite this article in press as: Tuon FF, et al. Risk factors for mort
carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2016. http://dx
r <50 years old.
Survival analysis conﬁrmed the aforementioned ﬁndings.
ombined therapy showed higher survival rate than inap-
ropriate therapy (p = 0.032) whereas survival of those withtreatment. Two active drugs showed fewer deaths (p < 0.05).
monotherapy was similar to those who received no active drug
(p = 0.129) or combined therapy (p = 0.113) (Fig. 1).
Discussion
KPC-producing K. pneumoniae is endemic in Southern Brazil
and it is among the most common pathogens in intensive
care units. Similar condition has occurred in Greece.10 This
may be associated with poor assistance conditions and low
healthcare professional qualiﬁcation in the intensive units. In
developed countries such situation is different and KPC is not
as important as Gram-positive cocci (Staphylococcus aureus).18
Some small case series have been published, but not exclu-
sively evaluating CRE-VAP. This is the ﬁrst study to focus
on risk factors for mortality associated with CRE-VAP. From
the 112 assessed patients, 81 (72.3%) received inappropriate
empirical treatment within 24 h. The most frequent empirical
treatment was the use of carbapenem, considered inadequate,
even in combined therapy, as none of the tested strains had a
MIC  < 8 mg/L. Probably due to increased MIC levels, we  could
not evidence superiority of carbapenem use in combined ther-
apies.
Combination therapy was previously associated with bet-
ter survival in a multivariate analysis of 41 patients with KPC
bacteremia reported by Qureshi et al. The 28-day mortality was
13.3% in the combination therapy group compared to 57.8% in
the monotherapy group (p = 0.01).20 In a review article of case
series of KPC infection treatment, Lee and Burgess have ana-
lyzed 38 articles with a total of 105 patients, of which 30%
had KPC pneumonia. From the total evaluated patients, 47%
received monotherapy and 53% received combination therapy,ality in patients with ventilator-associated pneumonia caused by
.doi.org/10.1016/j.bjid.2016.09.008
the global treatment failure rate was 36%. Among therapeutic
failure cases, the pulmonary site was the most frequent (47%),
followed by bacteremia (39%). In our study, more  treatment
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Table 1 – Risk factors analysis for ventilator-associated pneumonia caused by Carbapenem-resistant Enterobacteriaceae.
Continuous variables Death Survival p-Value
(n = 64) (n  = 48)
Meana SDc Mean SD
Age 61.7 19.0 45.9 19.6 <0.001f
ICU total admission 14.1 11.1 15.9 28.5 0.657
VM days 14.1 11.1 15.2 28.4 0.781
Total admission (days) 30.3 16.6 70.9 81.1 <0.001f
Days before VAP 19.0 13.0 18.1 28.6 0.826
Days after VAP 11.3 9.4 52.8 59.5 <0.001f
Charlson index 2.1 2.5 0.8 1.6  0.003f
APACHE 26.1  5.5 26.5 4.7 0.702
Categorical variables nb % n % p-Value
Gender (male) 39 60.9% 35 72.9% 0.109
Burn 2 3.1% 4 8.3% 0.209
HIV infection 1 1.6% 1 2.1% 0.671
Diabetes 10 15.6% 3 6.3% 0.122
Diabetes with complications 6 9.4% 2 4.2% 0.257
Chronic renal failure 8 12.5% 1 2.1% 0.046f
Previous myocardial infarction 9 14.1% 6 12.5% 0.533
Congestive heart failure 7 10.9% 2 4.2% 0.177
Peripheral artery disease 2 3.1% 0 0.0% 0.329
Previous stroke 10 15.6% 3 6.3% 0.122
Previous stroke with plegia 1 1.6% 1 2.1% 0.671
Dementia 3 4.7% 2 4.2% 0.641
COPD 4 6.3% 2 4.2% 0.492
Hypertension 31 48.4% 12 25.0% 0.011f
Neoplasm 9 14.1% 1 2.1% 0.028f
Lymphoma 1 1.6% 0 0.0% 0.575
Leukemia 0 0.0% 0 0.0% –
Metastatic tumor 5 7.8% 0 0.0% 0.059
Rheumatic disease 2 3.1% 1 2.1% 0.613
Peptic ulcer 0 0.0% 0 0.0% –
Hepatic disease 2 3.1% 1 2.1% 0.613
Cirrhosis 0 0.0% 1 2.1% 0.425
Chronic corticoid use 3 4.7% 0 0.0% 0.187
Other immunosuppressants 6 9.4% 1 2.1% 0.121
Trauma on admission 26 40.6% 28 58.3% 0.041f
Elective surgery 7 10.9% 5 10.4% 0.692
Emergency surgery 32 50.0% 29 60.4% 0.162
Treatment nb % n % p-Value
Incorrect treatment<24 h 45 70.3% 36 75.0% 0.390
Correct treatment <24 hd 19 29.7% 12 25.0% 0.390
Incorrect treatment <5 days 18 28.1% 11 22.9% 0.298
Correct treatment<5 days 46 71.9% 37 77.1% 0.298
Monotherapyd 40 62.5% 26 54.2% 0.276
Combined therapye 6 9.4% 11 22.9% 0.044f
a Mean of total deaths or survival.
b Number of cases.
c Standard deviation.
d At least one active drug.
e At least two active drugs.
f p < 0.05.
failures were seen in cases treated with monotherapy than in
those treated with combination therapy, but the small sample
size precluded deﬁnitive conclusions. The most common suc-Please cite this article in press as: Tuon FF, et al. Risk factors for mor
carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2016. http://dx
cessful regimen for treating pulmonary infections consisted
of tigecycline plus colistin (8 patients), followed by aminogly-
coside plus colistin (3 patients), but the overall failure rates
were not signiﬁcantly different in the three most commonlyused antibiotic combinations: polymyxin plus carbapenem,
polymyxin plus tigecycline, polymyxin plus aminoglycoside
(30%, 29%, and 25%, respectively, p = 0.06).tality in patients with ventilator-associated pneumonia caused by
.doi.org/10.1016/j.bjid.2016.09.008
Clinical trials are recruiting patients in order to identify
the best options, but the answer is still far away. The current
concept is to associate antibiotics for CRE, which is based on
retrospective studies showing reduced mortality.2,19,20
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Table 2 – Multivariate analysis of risk factors for ventilator-associated pneumonia caused by Carbapenem-resistant
Enterobacteriaceae.
Variable p-Value (univariate) B OR CI (95%) p-Value
Age > 50 years 0.003 0.11 3.39 1.27 9.17 0.016
Charlson index > 1 0.013 1.22 1.13 0.32 3.96 0.853
Chronic renal failure 0.046 0.11 0.90  0.34 2.38 0.825
Hypertension 0.011 2.14 8.55 0.78 94.21 0.080
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4. Lat A, Clock SA, Wu F, et al. Comparison of polymyxin B,
tigecycline, cefepime, and meropenem MICs for
KPC-producing Klebsiella pneumoniae by broth microdilution,Neoplasm 0.028 1.
Trauma on admission 0.041 0.
Oliveira et al. analyzed 118 patients with CRE infection
nd found polymyxin treatment as an independent risk fac-
or associated with higher mortality. Combined therapy in
uch study was not superior to monotherapy, but monother-
py with carbapenem was protective. The authors discussed
hat changes in CLSI breakpoints of enterobacteria for car-
apenems was based on in vitro data and that for clinical
urposes, carbapenems could be active when MIC is between
 and 4 mg/L. Furthermore, some authors have included a car-
apenem as third drug in regimens with two active drugs
hen the MIC  is less than 8 mg/L. However, no CRE showed this
attern in the present cases. This may be one of the explana-
ions for ineffectiveness of carbapenems in terms of CRE-VAP
urvival.
A recent meta-analysis showed that carbapenem combi-
ation should be revised, once it does not decrease mortality
nd is a potential harm for patients, considering side effects,
lostridium difﬁcile colitis, and resistance induction.21 In our
tudy, none of the therapeutic combinations was indepen-
ently associated with increased survival; however, combined
herapy within ﬁve days, with at least two active drugs, was
ssociated to a lower mortality (p = 0.044).
Some limitations of our study included the lack of sepsis
everity assessment upon onset of symptoms, evaluation of
ocal complications, such as empyema  and lung abscess, and
rug dosage. Colistin and tigecycline require a loading dose,
ven with renal failure. Aminoglycosides serum levels are not
outinely evaluated as well as daily dose adjustment of other
rugs according to renal clearance. However, even in patients
sing the recommend dosage, most of them in intensive
are units may not achieve adequate levels, despite pharma-
odynamic characteristics (Cmax:MIC for aminoglycosides,
UC:MIC for colistin/polymyxin or T%:MIC for carbapenem) in
pproved FDA dosages.22 Tigecycline requires very low serum
evels in order to be considered a safe drug in severe patients.
oreover, lung concentrations of all these drugs are not well
nown, even with perfect conditions of serum levels. Other
imitation comes from the study design including only two
ospitals. As it does not have external validity, we encourage
ther hospitals to compare combined therapy with monother-
py. The better outcome observed among patients receiving
ombined drugs until ﬁve days was interesting. It could mean
hat adding a second active drug could be recommended.
nfortunately, the small number of patients and the lack of
obust data precluded us from performing a multivariate anal-Please cite this article in press as: Tuon FF, et al. Risk factors for mort
carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2016. http://dx
sis.
Despite such limitations, our ﬁndings for VAP are in accor-
ance with the current evidence, which points to better results
ith combined therapy for CRE severe infections.3.34 0.29 38.65 0.334
1.55 0.56 4.33 0.401
In conclusion, patients with CRE-VAP treated with com-
bined therapy with two active drugs within ﬁve days have
lower mortality. In hospitals with high incidence of CRE, a
combined therapy with two active drugs should be initiated
until ﬁnal culture results become available or further publica-
tions proving otherwise.
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